- Stocks
- Pharma & Healthcare
- Coral Labs
Coral Labs share price
NSE: CORALABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Coral Labs at a glance
With a market capitalisation of ₹196 Cr, it ranks 2280th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 12.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹26 Cr (−5.9% year on year) and net profit ₹5 Cr (+84.5%), on a standalone basis. Promoters held 71.51% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹196 CrRank 2280 on NSE
- Price to book
- 1.25×FY25
- EPS (TTM)
- ₹45.86to Q4 FY26
- ROE
- 12.0%FY25
- ROCE
- 16.3%FY25
- Debt to equity
- 0.02FY25
- Net profit margin
- 21.0%FY25
- Book value / share
- ₹563.19FY25
- Dividend payout
- 3.0%FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Coral Labs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹32 Cr | ₹32 Cr | ₹23 Cr | ₹28 Cr | ₹19 Cr | ₹19 Cr | ₹22 Cr | ₹26 Cr |
| Revenue YoY | +133.7% | +39.2% | +27.2% | −2.6% | −40.6% | −41.0% | −6.2% | −5.9% |
| Net profit | ₹9 Cr | ₹6 Cr | ₹6 Cr | ₹3 Cr | ₹3 Cr | ₹6 Cr | ₹3 Cr | ₹5 Cr |
| Net profit YoY | +378.3% | +6.3% | +184.3% | −51.1% | −70.9% | −8.8% | −54.7% | +84.5% |
| Net margin | 27.8% | 19.8% | 26.7% | 10.1% | 13.6% | 30.6% | 12.9% | 19.7% |
| EPS | ₹24.64 | ₹17.86 | ₹17.20 | ₹7.91 | ₹7.18 | ₹16.29 | ₹7.77 | ₹14.62 |
Coral Labs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹71 Cr | ₹97 Cr | ₹76 Cr | ₹78 Cr | ₹84 Cr | ₹115 Cr |
| Operating profit | ₹9 Cr | ₹18 Cr | ₹11 Cr | ₹8 Cr | ₹21 Cr | ₹33 Cr |
| Net profit | ₹7 Cr | ₹14 Cr | ₹9 Cr | ₹6 Cr | ₹16 Cr | ₹24 Cr |
| EPS (₹) | ₹19.96 | ₹37.94 | ₹25.32 | ₹18.04 | ₹44.19 | ₹67.61 |
| Cash from operations | −₹4 Cr | ₹1 Cr | ₹6 Cr | ₹13 Cr | −₹5 Cr | −₹1 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹116 Cr | ₹137 Cr | ₹156 Cr | ₹155 Cr | ₹178 Cr | ₹201 Cr |
Coral Labs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% |
| Non-institutions | 28.49% | 28.49% | 28.49% | 28.49% | 28.49% | 28.49% |
Coral Labs vs peers
The listed Pharma & Healthcare companies nearest to Coral Labs by market capitalisation.
Ask anything about Coral Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against CORALAB's own history. Try: “Why has CORALAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on CORALAB over five years” · “Compare CORALAB with SYSCHEM on margins and valuation”
Frequently asked questions about Coral Labs
What is the market cap of Coral Labs?
Coral Labs' market capitalisation is ₹196 Cr (₹196 Cr) at the 22 Oct 2026 close, ranking 2280th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Coral Labs?
Return on equity was 12.0% in FY25 and return on capital employed was 16.3% in FY25 (standalone figures).
Is Coral Labs a debt-free company?
Coral Labs is close to debt-free: its debt-to-equity ratio was 0.02 in FY25.
What were Coral Labs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Coral Labs reported revenue of ₹26 Cr, −5.9% year on year, and net profit of ₹5 Cr, +84.5% year on year.
What is the shareholding pattern of Coral Labs?
As of 30 Jun 2026: promoters 71.51%, non-institutions 28.49%.
Who are Coral Labs' competitors?
The listed Pharma & Healthcare companies closest to Coral Labs by market cap are Syschem (India), Achyut Health, Aashka Hospital, Brooks Laboratories, OXYGENTA PHARMA and Accretion Nutra.
Is Coral Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Coral Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CORALAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text